Erin is a molecular cancer biologist, who has spent the last 10 years in the field of proteomics, utilising mass spectrometry to identify cancer biomarkers and understand molecular pathways that contribute to cancer progression.
Erin's work at ProCan focuses on translating the tens of thousands of cancer proteomes acquired in ProCan’s discovery projects into clinically applicable targeted proteomic assays using selected reaction monitoring (SRM). With these highly selective and robust assays, ProCan hopes to change the way in which patients are diagnosed and treated, selecting the most effective therapy for the individual.
Prior to her role at ProCan, Erin's research in the field of proteomics involved melanoma biomarker discovery for patient stratification, understanding the contribution of the unfolded protein response to cancer progression, the role of the PTM AMPylation in melanoma biology and the development of synthetic antibodies for immunotherapy targeting leukaemia’s.